To extend its cash runway into the second half of 2027 and focus resources on clinical programs, San Francisco–based Allogene Therapeutics is laying off 28% of employees, according to a May 13 SEC filing. The biotech, which is developing allogeneic CAR T products for cancer and autoimmune disease, had 229 employees as of March 1, according to an earlier filing, meaning the cuts could involve around 64 people.
